Equity Details
Price & Market Data
Price: $4.81
Daily Change: -$0.148 / 3.08%
Daily Range: $4.75 - $5.30
Market Cap: $58,680,200
Daily Volume: 408,450
Performance Metrics
1 Week: -3.82%
1 Month: -12.91%
3 Months: -29.77%
6 Months: 28.42%
1 Year: 20.35%
YTD: 10.37%
About Cingulate Inc. (CING)
Get quick and reliable data for Cingulate Inc. (CING). Price: 4.81, daily change: -$0.148 / 3.08%. Market cap: 58,680,200. Performance across all periods for informed decisions.
Company Details
Employees: 14
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.